Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
and probably has a role in inflammation and remodeling of the extracellular matrix, a process also involved in metastatic malignant diseases. High serum YKL ‐ 40 has been associated with poor prognosis ...
very high transcription levels of the genes CD44, YKL - 40 and IL-6, increased gene expression of TNF-α, and elevated serum concentrations of TNF-α, YKL - 40 and IL-6 and reduced serum concentration of CD44 ...
biomarker study, we examined the prognostic value of preoperative and postoperative serum YKL - 40 , IL-6, CRP, CEA, and CA19-9 in a cohort of 441 consecutive patients who had undergone liver resection for CRLM ...
. High serum YKL - 40 is associated with poor prognosis in patients with inflammatory diseases and cancer. We studied whether serum YKL - 40 was associated with systemic low-level inflammation, an immune risk ...
and CHI3L1, which encodes for YKL ‐ 40 , a putative prognosticator for various diseases, including cancer, were strongly up‐regulated in avascular glioma. In glioblastoma patients , these genes showed coregulation ...
for their willingness to participate. References 1. Johansen JS , Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL - 40 , a new prognostic biomarker in cancer patients ? [Review] . Cancer Epidemiol Biomarkers Prev 2006 ...
with inflammatory processes and have up-regulated levels (Rahimian and He 2017). Recently identify biomarker for HIVE patients show that YKL - 40 can serve as a biomarker of CSF in patients with HIV infection ...
isolated from serum or CSF in patients with high -grade gliomas (Table 1) and discuss their potential role in diagnosis, prognostication , identifying treatment response, and early detection of disease ...
as observed in the present study. In addition to tau, the neuroinflammation/ astroglial activation marker YKL - 40 also interacted with Aβ in predicting sleep. YKL - 40 in serum has been related to specific sleep ...
carcinoma antigen (SCC-Ag) is the serum marker for SCCs in clinical use. It is present at high levels in 20%–60% of patients with early stage CC. Abnormal levels of SCC-Ag are present in 64% of patients ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!